Regeneron Pharmaceuticals, Inc. at Wells Fargo Healthcare Conference Transcript
All right. Welcome, welcome, welcome. My name is Mohit Bansal. I'm one of the biotech and pharma analysts here at Wells Fargo. And I have the pleasure to start the day with the Regeneron management team, fifth year in a row.
In my five years at Wells Fargo, Regeneron has come here every year. So with us, we have Marion McCourt, the Chief Commercial Officer of the company; and Ryan Crowe, Head of IR at the company. So I'll give the podium to Ryan to talk about some.
Yes. I appreciate you having us, Mohit, five years. It's flown by a lot of successes that we've been able to report at this very conference and excited to be back. So thank you. Thank you.
Before we begin, I just need to make a couple of forward-looking statement disclaimers. I would like to remind you that remarks made today may include forward-looking statements about Regeneron, and each forward-looking statement is subject to risks and uncertainties that could cause
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
